Cross-sectional study assesses Medicare Part D coverage and out-of-pocket costs for GLP-1 receptor agonists, highlighting implications of the Inflation Reduction Act.
This cross-sectional study examines Medicare Part D coverage and out-of-pocket costs for glucagon-like peptide-1 receptor agonists following implementation of the Inflation Reduction Act.
No takes yet. Share an insight, caveat, or question.
Klebanoff et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: